Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    Immix Biopharma, Inc. (IMMX)

    8.06 +0.86 (+11.94%)
    At close: November 6 at 4:00:01 PM EST
    7.99 -0.07 (-0.87%)
    After hours: November 6 at 4:17:02 PM EST
    Trade IMMX on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for IMMX
    • Previous Close 7.20
    • Open 7.24
    • Bid 5.87 x 200
    • Ask 9.22 x 200
    • Day's Range 7.18 - 8.17
    • 52 Week Range 3.16 - 15.10
    • Volume 1,444,883
    • Avg. Volume 1,516,496
    • Market Cap (intraday) 668.198M
    • Beta (5Y Monthly) 0.29
    • PE Ratio (TTM) --
    • EPS (TTM) -0.88
    • Earnings Date (est.) Nov 9, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 24.05
    • Moby Rating Bear

    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

    www.immixbio.com

    21

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Immix Biopharma, Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    IMMX
    54.11%
    S&P 500 (^GSPC)
    7.76%

    1-Year Return

    IMMX
    166.01%
    S&P 500 (^GSPC)
    9.77%

    3-Year Return

    IMMX
    87.01%
    S&P 500 (^GSPC)
    68.96%

    5-Year Return

    IMMX
    61.20%
    S&P 500 (^GSPC)
    57.04%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings -11.56M
    Profit Margin 0.00%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    -10M
    -8M
    -6M
    -4M
    -2M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    17.40
    24.05 Average
    8.06 Current
    30.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 9/29/2026
    Analyst Needham
    Rating Action Maintains
    Rating Buy
    Price Action Raises
    Price Target 21 -> 30
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -20.52%

    • Return on Equity (ttm)

      -34.18%

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -39.92M

    • Diluted EPS (ttm)

      -0.88

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      232.11M

    • Total Debt/Equity (mrq)

      0.44%

    • Levered Free Cash Flow (ttm)

      -25.39M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    BFRI Biofrontera Inc.
    0.8280 +8.94%
    KTTA Pasithea Therapeutics Corp.
    0.5788 +11.52%
    ENSC Ensysce Biosciences, Inc.
    0.3287 -7.23%
    PTPI Petros Pharmaceuticals, Inc.
    0.0030 0.00%
    NRSN NeuroSense Therapeutics Ltd.
    1.6800 +8.28%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: